Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Unternehmen & Branche
| Name | IDEAYA Biosciences, Inc. |
|---|---|
| Ticker | IDYA |
| CIK | 0001676725 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 2,55 Mrd. USD |
| Beta | 0,02 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 218,710,000 | -113,698,000 | -1.28 | 1,109,324,000 | 1,022,934,000 |
| 2025-09-30 | 10-Q | 207,834,000 | 119,244,000 | 1.33 | 1,185,136,000 | 1,092,034,000 |
| 2025-06-30 | 10-Q | -77,491,000 | -0.88 | 1,041,270,000 | 959,653,000 | |
| 2025-03-31 | 10-Q | -72,178,000 | -0.82 | 1,100,641,000 | 1,024,135,000 | |
| 2024-12-31 | 10-K | 7,000,000 | -274,477,000 | -3.36 | 1,124,091,000 | 1,059,147,000 |
| 2024-09-30 | 10-Q | 0 | -51,821,000 | -0.60 | 1,239,873,000 | 1,180,418,000 |
| 2024-06-30 | 10-Q | 0 | -52,772,000 | -0.68 | 973,663,000 | 931,658,000 |
| 2024-03-31 | 10-Q | 0 | -39,572,000 | -0.53 | 961,527,000 | 935,311,000 |
| 2023-12-31 | 10-K | 23,385,000 | -112,961,000 | -1.96 | 649,316,000 | 621,090,000 |
| 2023-09-30 | 10-Q | 8,038,000 | -27,440,000 | -0.46 | 532,942,000 | 508,049,000 |
| 2023-06-30 | 10-Q | 3,544,000 | -27,926,000 | -0.50 | 527,557,000 | 501,609,000 |
| 2023-03-31 | 10-Q | 7,880,000 | -23,640,000 | -0.49 | 364,746,000 | 333,810,000 |
| 2022-12-31 | 10-K | 50,931,000 | -58,655,000 | -1.42 | 387,969,000 | 349,455,000 |
| 2022-09-30 | 10-Q | 29,699,000 | 1,615,000 | 0.04 | 410,907,000 | 368,769,000 |
| 2022-06-30 | 10-Q | 5,851,000 | -22,056,000 | -0.57 | 338,007,000 | 269,321,000 |
| 2022-03-31 | 10-Q | 11,359,000 | -14,013,000 | -0.36 | 358,867,000 | 288,667,000 |
| 2021-12-31 | 10-K | 27,941,000 | -49,762,000 | -1.41 | 381,347,000 | 301,514,000 |
| 2021-09-30 | 10-Q | 8,976,000 | -11,582,000 | -0.31 | 399,444,000 | 317,629,000 |
| 2021-06-30 | 10-Q | 8,756,000 | -10,947,000 | -0.33 | 328,401,000 | 240,260,000 |
| 2021-03-31 | 10-Q | 7,247,000 | -9,021,000 | 326,097,000 | 233,125,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Stein Jeffrey | Director | Open Market Purchase | 50,000 | 32.96 | 1,647,890.00 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.